C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/11 (2006.01)
Patent
CA 2705714
The present invention relates to oligomer compounds (oligomers), which target the androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain medical disorders, such as a disease or a medical disorder as disclosed herein, such as a hyperproliferative disorder, such as cancer.
La présente invention porte sur des composés oligomères (oligomères) qui ciblent l'ARNm du récepteur de l'androgène dans une cellule, conduisant à une expression réduite du récepteur de l'androgène. La réduction de l'expression du récepteur de l'androgène est utile pour le traitement de certains troubles médicaux, tels qu'une maladie ou un trouble médical tel que décrit ici, notamment une maladie hyperproliférative telle que le cancer.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Enzon Pharmaceuticals Inc.
Santaris Pharma A/s
LandOfFree
Lna antagonists targeting the androgen receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lna antagonists targeting the androgen receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lna antagonists targeting the androgen receptor will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1688659